<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1119">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05146583</url>
  </required_header>
  <id_info>
    <org_study_id>NYP19-04020103</org_study_id>
    <nct_id>NCT05146583</nct_id>
  </id_info>
  <brief_title>Injection of Autologous Bone Marrow Aspirate in Patients With Degenerative Disc Disease.</brief_title>
  <official_title>Injection of Autologous Bone Marrow Aspirate in Patients With Degenerative Disc Disease: a Phase I Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York Presbyterian Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York Presbyterian Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lumbar discectomy and injection of purified cellular bone marrow concentrate or lumbar&#xD;
      discectomy only&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to find a regenerative treatment for back pain from DDD, cell based therapies have&#xD;
      become of increasing interest. Recent clinical studies have shown promising improvement in&#xD;
      pain and disc hydration, thus indicating a regenerative effect.&#xD;
&#xD;
      The use of mesenchymal stem cells for regeneration of degenerated connective tissue of&#xD;
      mesenchymal origin has proven efficient in multiple recent studies1-3. However, the&#xD;
      acquisition of mesenchymal stem cells (MSC) is always an extensive procedure requiring either&#xD;
      enzymatic or genetic manipulation of acquired tissues. Thus, the use of these MSCs is highly&#xD;
      controversial and raises concerns in terms of patient safety.&#xD;
&#xD;
      One of the most commonly used sources for MSCs is bone marrow tissue. Even when not&#xD;
      manipulated, these tissues already contain a significant amount of mesenchymal stem cells and&#xD;
      growth factors. Therefore, they are used for regenerative treatments of multiple degenerative&#xD;
      musculoskeletal diseases4-7.&#xD;
&#xD;
      This is an exploratory pilot study which aims to compare patient outcomes between two&#xD;
      treatments approaches for DDD that are currently being used in clinic. While micro-&#xD;
      discectomy is the standard of care for DDD, micro-discectomies with autologous bone marrow&#xD;
      cell injections have been used in clinic in the past year. The goal of this study is to&#xD;
      determine if the bone marrow injection group is superior compared to the control group (state&#xD;
      of the art micro-discectomies) in enhancing degenerative disc recovery and improving or&#xD;
      preventing back pain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Numeric Rating for Back pain at 12 months</measure>
    <time_frame>Baseline, 3 months, 6 months, 12 months after surgery</time_frame>
    <description>0 to 10 NRS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Oswestry Disability Index at 12 months</measure>
    <time_frame>Baseline, 3 months, 6 months, 12 months after surgery</time_frame>
    <description>0 to 100 PROM to measure low back disfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disc Height Index</measure>
    <time_frame>Baseline and 12 months or longer folllow-up after surgery</time_frame>
    <description>MRI measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pfirrman grading</measure>
    <time_frame>Baseline and 12 months or longer folllow-up after surgery</time_frame>
    <description>MRI measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NRS Leg pain</measure>
    <time_frame>Baseline, 3 months, 6 months, 12 months after surgery</time_frame>
    <description>0 to 10 NRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>Continrous monitoring during study during one year after surgery</time_frame>
    <description>Infections, reoperations, blood loss.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Lumbar Disc Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Autologous bone marrow aspirate</intervention_name>
    <description>Harvested from SI-joint</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with symptomatic lumbar disc herniation and discogenic back pain who meet the&#xD;
        inclusion criteria may be eligible for this procedure.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients â‰¥18 years of age&#xD;
&#xD;
          2. Radiologically (MRI) confirmed diagnosis degenerative disc disease of the lumbar spine&#xD;
             and/or lumbar disc herniation&#xD;
&#xD;
          3. Unresponsive to conservative/non-operative treatment for &gt;3 months&#xD;
&#xD;
          4. Psychosocial, mental and physical ability to understand and to adhere to this&#xD;
             protocol, especially adhering to the visit schedule follow-ups, and observe treatment&#xD;
             plan&#xD;
&#xD;
          5. Signed and dated informed consent document prior to any study-related procedures&#xD;
             indicating that the patient has been informed of all pertinent aspects of the trial&#xD;
             study-related procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or breastfeeding patients&#xD;
&#xD;
          2. Active malignancy&#xD;
&#xD;
          3. Active chronic or acute infection&#xD;
&#xD;
          4. Autoimmune disorder that impacts the lumbar spine (Ankylosing spondylitis, lupus eg.)&#xD;
&#xD;
          5. Acute Episode or major mental illness&#xD;
&#xD;
          6. Major cognitive impairment causing to inability to understand informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roger Hartl, Prof.dr.</last_name>
    <phone>(212) 821-0850</phone>
    <email>ermabell@cornell.edu.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pravesh Gadjradj, MD</last_name>
    <phone>(212) 821-0850</phone>
    <email>psg4001@med.cornell.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>New York Presbytarian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pravesh S Gadjradj, MD</last_name>
      <phone>212-821-0850</phone>
      <email>psg4001@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brendan Mendary, BS</last_name>
      <phone>(212) 821-0850</phone>
      <email>brm4011@med.cornell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Larry Bonassar, Prof.dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roger Hartl, Prof.dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sertac Kernaz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rachel Yerden, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 10, 2021</study_first_submitted>
  <study_first_submitted_qc>November 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2021</study_first_posted>
  <last_update_submitted>November 22, 2021</last_update_submitted>
  <last_update_submitted_qc>November 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York Presbyterian Hospital</investigator_affiliation>
    <investigator_full_name>Pravesh Gadjradj</investigator_full_name>
    <investigator_title>on behalf of PI: Prof.dr.R.Hartl</investigator_title>
  </responsible_party>
  <keyword>Sciatica</keyword>
  <keyword>Lumbar Disc Herniation</keyword>
  <keyword>Discectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Diseases</mesh_term>
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

